Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Dec;30(6):884–888. doi: 10.1111/j.1365-2125.1990.tb05455.x

An evaluation of the alpha-adrenoceptor antagonism produced by SK&F 86466 in healthy normotensive males.

R F Schafers 1, H L Elliott 1, C A Howie 1, J L Reid 1
PMCID: PMC1368310  PMID: 1981137

Abstract

SK&F 86466 is a novel, potent alpha-adrenoceptor antagonist which, in animal experiments, is reported to show a high selectivity for alpha 2-adrenoceptors at both pre- and post-junctional sites. The effects of two intravenous doses of 80 and 200 micrograms kg-1 of SK&F 86466 were assessed in a placebo-controlled, double-blind, randomised study in eight young, healthy, normotensive males. Two indices of alpha-adrenoceptor activity were investigated: i) Pressor responsiveness to the relatively selective alpha 1-adrenoceptor agonist phenylephrine and to the preferential alpha 2-adrenoceptor agonist alpha-methylnoradrenaline. ii) Circulating levels of noradrenaline. SK&F 86466 at a dose of 200 micrograms kg-1 produced rightward shifts of the pressor dose-response curves to both agonists: a 1.4 fold shift for phenylephrine (P = 0.023) and a 1.6 fold shift for alpha-methylnoradrenaline (P = 0.051). Erect plasma noradrenaline sampled at 105 min into the infusion was significantly increased from 2.9 to 5.0 nmol l-1 by SK&F 86466 200 micrograms kg-1 (P = 0.002). The change in the phenylephrine responses indicates post-junctional alpha 1-adrenoceptor blockade and the rise in noradrenaline is consistent with pre-junctional alpha 2-adrenoceptor antagonist activity. Overall the results of this study suggest that SK&F 86466, at a dose of 200 micrograms kg-1, causes both alpha 1- and alpha 2-adrenoceptor antagonism in human subjects.

Full text

PDF
888

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown M. J., Struthers A. D., Burrin J. M., Di Silvio L., Brown D. C. The physiological and pharmacological role of presynaptic alpha- and beta-adrenoceptors in man. Br J Clin Pharmacol. 1985 Dec;20(6):649–658. doi: 10.1111/j.1365-2125.1985.tb05124.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bylund D. B. Heterogeneity of alpha-2 adrenergic receptors. Pharmacol Biochem Behav. 1985 May;22(5):835–843. doi: 10.1016/0091-3057(85)90536-2. [DOI] [PubMed] [Google Scholar]
  3. Elliott H. L., Reid J. L. Evidence for postjunctional vascular alpha 2-adrenoceptors in peripheral vascular regulation in man. Clin Sci (Lond) 1983 Sep;65(3):237–241. doi: 10.1042/cs0650237. [DOI] [PubMed] [Google Scholar]
  4. Hieble J. P., DeMarinis R. M., Fowler P. J., Matthews W. D. Selective alpha-2 adrenoceptor blockade by SK&F 86466: in vitro characterization of receptor selectivity. J Pharmacol Exp Ther. 1986 Jan;236(1):90–96. [PubMed] [Google Scholar]
  5. Howes L. G., Miller S., Reid J. L. Simultaneous assay of 3,4-dihydroxyphenylethylene glycol and norepinephrine in human plasma by high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1985 Mar 22;338(2):401–403. doi: 10.1016/0378-4347(85)80111-0. [DOI] [PubMed] [Google Scholar]
  6. Jie K., van Brummelen P., Vermey P., Timmermans P. B., van Zwieten P. A. Modulation of noradrenaline release by peripheral presynaptic alpha 2-adrenoceptors in humans. J Cardiovasc Pharmacol. 1987 Apr;9(4):407–413. doi: 10.1097/00005344-198704000-00005. [DOI] [PubMed] [Google Scholar]
  7. Ruffolo R. R., Jr Interactions of agonists with peripheral alpha-adrenergic receptors. Fed Proc. 1984 Nov;43(14):2910–2916. [PubMed] [Google Scholar]
  8. Sumner D. J., Elliott H. L. The pressor dose-response in clinical cardiovascular pharmacology. Br J Clin Pharmacol. 1987 May;23(5):499–503. doi: 10.1111/j.1365-2125.1987.tb03084.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Sumner D. J., Elliott H. L., Vincent J., Reid J. L. A pragmatic approach to the pressor dose-response as an index of vascular reactivity and adrenoceptor function in man. Br J Clin Pharmacol. 1987 May;23(5):505–510. doi: 10.1111/j.1365-2125.1987.tb03085.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. de Mey C., Enterling D., Hansen-Schmidt S., Meineke I. SK&F 86466, a novel alpha-adrenolytic drug: effects on heart rate, blood pressure, and neuroendocrine function in supine resting position and in response to postural and cold stimulation in normal humans. J Cardiovasc Pharmacol. 1989 Jan;13(1):25–31. [PubMed] [Google Scholar]
  11. van Brummelen P., Jie K., van Zwieten P. A. Alpha-adrenergic receptors in human blood vessels. Br J Clin Pharmacol. 1986;21 (Suppl 1):33S–39S. doi: 10.1111/j.1365-2125.1986.tb02851.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES